Studies Demonstrate Ipsen s Ongoing Commitment to Innovation and Improving Patient Care in Neuroendocrine Tumors Paris , 28 February 2019 - Ipsen today announced that.
The proceeds of a hugely successful charity concert in Ardee Co.Louth are being used to increase awareness of a rare form of cancer, neuroendocrine tumours.
Chennai (Tamil Nadu) [India], September 20 (ANI/BusinessWire India): Rela Hospital, a Multi-Speciality Quaternary Care Hospital at Chrompet, Chennai launched the "Centre of Excellence for Neuroendocrine Tumors" to provide the highest standard of care and expertise to patients with Neuroendocrine Tumours in India. The centre was inaugurated by Noble Laureate, Prof Ada E.Yonath, who won the Nobel Prize in Chemistry in 2009 for her pioneering discoveries on the structure and function of ribosomes, the protein synthesizers in cells, other renowned researchers and scientists, in the presence of Dr Ilankumaran Kaliamoorthy, CEO, Rela Hospital. Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. Neuroendocrine cells have traits similar to those of nerve cells and hormone-producing cells. A neuroendocrine tumor can start in almost any organ throughout the body, and it most commonly occurs in the gastrointestinal or GI tract, as well as the l
MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it
Chimeric Therapeutics Ltd (ASX:CHM) has been issued a patent from the Unites States Patent and Trademark Office covering certain applications of chimeric.